# Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT00967057** · PHASE3 · COMPLETED · sponsor: **Children's Cancer and Leukaemia Group** · enrollment: 470 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** asparaginase
- **DRUG:** dexamethasone
- **DRUG:** idarubicin
- **DRUG:** methotrexate
- **DRUG:** mitoxantrone hydrochloride
- **DRUG:** pegaspargase
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00967057
- **Lead sponsor:** Children's Cancer and Leukaemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2010-01
- **Final completion:** 2011-12
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967057, "Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00967057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*